Hazard ratio of progression-free survival is an excellent predictor of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for extensive-disease small-cell lung cancer

Hao Chen, Nobuyuki Horita, Kentaro Ito, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko